News
Portfolio Company News
- July 12, 2010
Ablynx - Novartis Obtains Licenses to Develop and Commercialise Two Novel Nanobodies
- July 06, 2010
Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets
- July 05, 2010
Ablynx Secures €1.5 Million In Grants
- July 05, 2010
LifeCycle Pharma Announces Positive Results of Phase 2 Clinical Trial For LCP-Tacro™ in De Novo Kidney Transplant Patients
- July 02, 2010
Sunesis' $28.5M Stock Sale to Fund Voreloxin Phase III Trial
- July 01, 2010
Calistoga's $40M Series C Moves PI3K Inhibitor to Trial
- June 30, 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing - June 28, 2010
Metabolex To Advance Diabetes Drugs With Two Lucrative Partnerships - June 28, 2010
Ablynx Wins European mediscience Award for the Second year in a Row
- June 23, 2010
Ceregene Awarded Funding From Michael J. Fox Foundation
- June 23, 2010
Metabolex, J&J Unit Sign $330M Deal for Type II Diabetes Drugs
- June 22, 2010
Cerenis Therapeutics Reported Data from a Proof-of-Concept Phase I Study for the CER-627 Program - June 21, 2010
FoldRx: Unfolding the Money - June 16, 2010
FoldRx Gets $29M Venture Round, to Seek First Approval
- June 15, 2010
Calistoga Pharmaceuticals Presented Preclinical and Clinical Data on CAL-101 - June 14, 2010
Esperion Therapeutics and Cleveland Clinic Establish Collaboration for Research Related to HDL Therapies
- June 13, 2010
Final Data on Phase II Trial with IPH 1101 in Follicular Non-Hodgkin’s Lymphoma Reported at the EHA Meeting
- June 08, 2010
Calistoga Pharmaceuticals Presents Updated Data on CAL-101 - June 08, 2010
ChemGenex Pharmaceuticals Reports Positive Safety Findings for its Lead Product Candidate, Omapro - June 08, 2010
Sunesis Pharmaceuticals Repoprts Updated Phase II Data on Voreloxin in Combination with Cytarabine
< Previous | Next >
